IAP Drug Formulary - Editorial
Dr. G V Basavaraja - IAP President 2024


I hope this message finds you in good health and high spirits. It is with great pleasure and enthusiasm that I congratulate the release of the much-awaited IAP Pediatric Drug Formulary for the year 2024.

It gives me immense pride to witness the fruition of our collective efforts in compiling this comprehensive resource. The IAP Pediatric Drug Formulary serves as an indispensable tool for pediatricians across the country, providing up-to-date information on medications tailored specifically for pediatric patients.

In today's rapidly evolving medical landscape, ensuring the safe and effective use of medications in children is paramount. The IAP Pediatric Drug Formulary reflects the latest advancements in pediatric pharmacotherapy, incorporating evidence-based recommendations and guidelines endorsed by experts in the field.

With this new edition, we have expanded and refined our selection of drugs, encompassing a wide range of therapeutic categories commonly encountered in pediatric practice. Whether it be antibiotics, analgesics, antipyretics, or immunizations, the formulary equips practitioners with the knowledge they need to make informed decisions for their young patients.

Furthermore, in recognition of the diverse healthcare settings across our nation, the formulary incorporates practical considerations for resource-limited settings, ensuring accessibility without compromising quality of care.

I extend my heartfelt gratitude to the dedicated members of the IAP Drug Formulary Committee for their meticulous work in curating this invaluable resource. Their expertise and commitment to excellence have undoubtedly contributed to the success of this endeavor.

As we continue to uphold our mission of promoting the health and well-being of children in India, let us embrace the IAP Pediatric Drug Formulary as a cornerstone of our clinical practice. Together, let us strive to provide the highest standard of care for our pediatric patients, ensuring their optimal health and development.

Thank you for your unwavering support and dedication to the field of pediatrics. I encourage each of you to utilize the IAP Pediatric Drug Formulary 2024 in your daily practice and share your feedback for continuous improvement.


Wishing you continued success and fulfillment in your endeavors.


Warm regards,

Dr. G V Basavaraja,

Professor, Pediatrics and Critical Care,

 IAP National President 2024